The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

by He YY, Liu ST, Mattei J, Bunn Jr PA, Zhou CC, Chan D
Published 2018-04-01